Is compounded semaglutide still legal in 2026?

What is already illegal, and since when

The semaglutide shortage began in 2022. Under federal law, a declared shortage lets licensed pharmacies compound drugs that are "essentially a copy" of a scarce branded product, and thousands of 503A and 503B pharmacies did exactly that, building a multibillion-dollar market for compounded semaglutide priced well below Ozempic and Wegovy's list rates. For background on how that infrastructure is regulated, see how compounding pharmacies work.

On February 21, 2025, the FDA declared the semaglutide shortage resolved. The exemption that let 503B outsourcing facilities bulk-compound semaglutide expired that day, because semaglutide did not appear on the separate 503B Bulks List. Tirzepatide followed about a month later, clearing its own shortage on March 19, 2025. Since then, both drugs have sat in the same legal bracket: 503B is closed, and it has been closed for a year and a half, not since some new 2026 crackdown.

What the April 30, 2026 proposal actually does

The FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List does not reopen anything or shut anything new. It locks a door that has already been shut since February 2025. If finalized, the exclusion would apply permanently, meaning a future shortage declaration could not reopen the 503B pathway the way the 2022 shortage originally did.

The agency's stated reasoning centers on supply and safety. Wegovy and Ozempic are available in multiple strengths with stable commercial supply, and the FDA logged 455 adverse event reports tied to compounded semaglutide as of early 2025, a higher count than the 320 tied to compounded tirzepatide over the same period. The agency concluded the access benefit of a 503B pathway no longer outweighs the risk.

The 503A window: still open, still narrow

A 503B facility produces large batches under FDA registration and can only work from the 503B Bulks List or an active shortage listing. A 503A pharmacy fills one prescription for one named patient, under a prescriber's order and state board oversight, and it is not bound by the 503B Bulks List at all. That is why the April proposal, aimed squarely at 503B, leaves 503A compounding largely where it already stood.

What 503A compounding is still bound by is the "essentially a copy" rule: a pharmacy cannot compound a product that is essentially the same as a commercially available drug unless there is a documented clinical reason. Cost is not that reason. Convenience is not that reason. A confirmed allergy to an inactive ingredient in Wegovy or Ozempic, or a dosing need the commercial pen genuinely cannot meet, is the kind of justification that holds up. Those situations are real but uncommon, and the prescriber has to put the reasoning in writing before the pharmacy fills anything.

Why the adverse event numbers matter here

The 455-to-320 gap between semaglutide and tirzepatide adverse event reports is not really about the drug itself. It is mostly about the container. Compounded semaglutide commonly ships as a multi-dose vial, and the patient draws up their own dose with a syringe. Semaglutide doses range from 0.25mg up to 2.4mg across the titration schedule, so a small measurement error at the low end is a large percentage error. Branded Wegovy uses a fixed-dose auto-injector pen. There is no calculation, no vial, no syringe. That difference in the delivery mechanism, not some unique hazard in the compounded molecule, accounts for most of the gap the FDA is citing.

The workaround: what "modified" compounding still looks like

Roughly 80% of compounded GLP-1 prescriptions by late 2025 included an added ingredient, most often B6 or B12, which changes the formulation enough to move it outside the "essentially a copy" classification under current FDA interpretation. B vitamins have a documented clinical rationale, since they can help manage GLP-1-related nausea, so this is not purely a loophole. But it is also the mechanism keeping a meaningful share of 503A compounding legally intact, and it is worth understanding if a pharmacy offers you a semaglutide-plus-B12 formulation and calls it something other than a straight copy of Wegovy.

The price war changed the calculation

The clearest reason compounded semaglutide is shrinking as an option is not just enforcement. It is that branded semaglutide got dramatically cheaper. Novo Nordisk launched a multi-month subscription program in March 2026 that brings self-pay Wegovy, injection or pill, to $249 a month on a 12-month term, with some plans offering an introductory $199 rate, down from a $1,349 list price. Ozempic prescribed off-label for weight loss has no equivalent subscription and still runs upward of $900 a month without insurance, so the drug you ask for still matters for cost. For a fuller cost breakdown across compounded and branded options, see what semaglutide costs online.

The same month, Novo Nordisk resolved a patent dispute with one of the telehealth platforms that had been selling a compounded version of its pill, and that platform agreed to stop marketing compounded semaglutide and instead sell the branded product. That settlement is a small case study in the broader pattern: legal pressure and price competition together, not enforcement alone, are what is actually shrinking the compounded market.

What to do if you are using compounded semaglutide right now

If your only reason for compounded semaglutide was price, it is worth pricing out the current Wegovy subscription before renewing anything. At $249 a month with FDA manufacturing standards and a fixed-dose pen, the gap that used to justify compounded pricing has narrowed substantially. If you have a genuine documented medical reason, that conversation belongs between you and your prescriber, with the justification in writing and a licensed 503A pharmacy filling the order. For the full picture across both semaglutide and tirzepatide, including where the tirzepatide timeline runs about a month behind this one, see our tirzepatide compounding breakdown and the full compounded GLP-1 landscape.

Is compounded semaglutide legal in 2026: the bottom line

Most of this question was settled in February 2025, not by anything that happened this summer. 503B bulk compounding of semaglutide ended then. The April 2026 proposal, still awaiting a final rule as of this writing, would mostly make that exclusion permanent rather than change what is available to you today. A 503A window remains for documented medical need, and it is genuinely narrow. For most people paying out of pocket, the more relevant development this year is not the rulemaking, it is that branded Wegovy now costs a fraction of what it did two years ago.